Kinetics of maternally acquired anti-hepatitis A antibodies: Prediction of waning based on maternal or cord blood antibody levels

Brinkhof, Martin W. G.; Mayorga, Orlando; Bock, Jürgen; Heininger, Ulrich; Herzog, Christian

doi:10.1016/j.vaccine.2013.01.011

Cited by 25 publications

(20 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antibody levels of umbilical cord blood are similar or higher than those of the mother (21)(22)(23). To investigate maternal seroprevalence, there are no issues related to using umbilical cord blood.…”

Section: Discussionmentioning

confidence: 99%

Time-Series Analysis Comparing the Prevalence of Antibodies against Nine Viral Species Found in Umbilical Cord Blood in Japan

et al. 2016

View full text Add to dashboard Cite

SUMMARY:In this study, we investigated the prevalence of antibodies against 9 viral species found in umbilical cord blood from 561 neonates in 2013. Serum IgG antibodies against the following viruses were measured: herpes simplex virus (HSV), varicella-zoster virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), human herpesvirus 6 (HHV-6), measles virus (MV), rubella virus (RV), mumps virus (MuV), and human parvovirus B19 (HPV B19). A survey questionnaire regarding past medical history and maternal immunization status for the vaccine-preventable diseases of varicella, measles, rubella, and mumps was simultaneously administered. The results were compared with previous data collected in 2001-2002 from 378 umbilical cord blood samples. Viral seroprevalence data were: HSV, 54z; VZV, 96z; EBV, 96z; CMV, 67z; HHV-6, 100z; MV, 95z; RV, 94z; MuV, 64z; and HPV B19, 55z. The seroprevalence of CMV, MV, and MuV were significantly lower in 2013 than in 2001 -2002 MV, 98z; MuV, 93z). Compared with the 2001-2002 data, the mean IgG antibody values of the 4 vaccine-preventable diseases were significantly lower, and vaccination coverage for those diseases among mothers was significantly higher. Thus, attention should be paid to antibody levels in women of childbearing age in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Time-Series Analysis Comparing the Prevalence of Antibodies against Nine Viral Species Found in Umbilical Cord Blood in Japan

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In the analysis of the 1995/96 and 2003 cross-sectional prevalence data children <1 year old were excluded because their antibody results (low levels of 12–653 mIU/ml) do not represent the cumulative risk of infection in the first year of life but, reflect – as documented with other infant data from León [11] - the presence of maternal antibodies. As described in detail by others [12], [13], [14], the observed age-specific prevalence of anti-HAV antibodies is a function of the age-specific annual risk of infection.…”

Section: Methodsmentioning

confidence: 99%

Decreasing Risk of Hepatitis A Infection in León, Nicaragua: Evidence from Cross-Sectional and Longitudinal Seroepidemiology Studies

et al. 2014

Self Cite

View full text Add to dashboard Cite

Background and ObjectivesNicaragua is highly endemic for hepatitis A. We aimed to provide an estimate of the change in the age-specific risk of hepatitis A virus (HAV) infection based on serological data from cross-sectional and longitudinal samples collected in León, Nicaragua, in 1995/96 (n = 979) and 2003 (n = 494).MethodsThe observed age-specific prevalence of anti-HAV antibodies was correlated to the age-specific risk of infection by calculating the probability of freedom from infection at a specific age.ResultsThe proportion of seropositive children aged 1.5 to 6 years was 42% in 2003 compared to 67% in 1995/96. Estimated annual risk of infection for a 3-year old child was 30% (95% CI: 27.0%, 33.1%) in 1995 and 15.5% (95% CI: 12.4%, 19.0%) in 2003. There was good agreement between estimates based on cross-sectional and longitudinal data. The age-specific geometric mean of the quantified anti-HAV antibody levels assessed in 2003 was highest at age 4 and decreased steadily up to age 40.ConclusionsThe substantially lower risk of HAV infection in 2003 than in 1995 for young children indicates a beginning transition from high to intermediate endemicity in León, Nicaragua. Consecutive age-stratified serosurveys are useful to assess changes in risk of infection following public health interventions. The decreasing age-specific GMC of anti-HAV antibodies during adulthood in a country with endemic HAV indirectly suggests that ongoing HAV exposure in the community has marginal boosting effect on antibody levels once protective immunity has been established by natural infection.

show abstract

“…These antigen-specific antibody titers decrease passively (decay) after clearance of the virus from the circulation but may be boosted upon re-exposure to the specific antigen in the course of reactivation or reinfection with a different CMV genotype [10]. In the absence of immunological boosts, virus-specific antibodies decay exponentially [11,12]. However, knowledge about the kinetic of virus-specific antibodies in association with that of total antibody levels is very limited in healthy individuals and CLL patients.…”

Section: Introductionmentioning

confidence: 99%

Chronic Lymphocytic Leukemia Patients Have a Preserved Cytomegalovirus-Specific Antibody Response despite Progressive Hypogammaglobulinemia

et al. 2013

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) is characterized by progressive hypogammaglobulinemia predisposing affected patients to a variety of infectious diseases but paradoxically not to cytomegalovirus (CMV) disease. Moreover, we found reactivity of a panel of CLL recombinant antibodies (CLL-rAbs) encoded by a germ-line allele with a single CMV protein, pUL32, despite differing antibody binding motifs. To put these findings into perspective, we studied prospectively relative frequency of viremia, kinetics of total and virus-specific IgG over time, and UL32 genetic variation in a cohort of therapy-naive patients (n=200). CMV-DNA was detected in 3% (6/200) of patients. The decay of total IgG was uniform (mean, 0.03; SD, 0.03) and correlated with that of IgG subclasses 1-4 in the paired samples available (n=64; p<0.001). Total CMV-specific IgG kinetics were more variable (mean, 0,02; SD, 0,06) and mean decay values differed significantly from those of total IgG (p=0.034). Boosts of CMV-specific antibody levels were observed in 49% (22/45) of CMV-seropositive patients. In contrast, VZV- and EBV-specific IgG levels decayed in parallel with total IgG levels (p=0.003 and p=0.001, respectively). VZV-specific IgG even became undetectable in 18% (9/50) of patients whereas CMV-specific ones remained detectable in all seropositive patients. The observed CMV-specific IgG kinetics were predicated upon the highly divergent kinetics of IgG specific for individual antigens - glycoprotein B-specific IgG were boosted in 51% and pUL32-specific IgG in 32% of patients. In conclusion, CLL patients have a preserved CMV-specific antibody response despite progressive decay of total IgG and IgG subclasses. CMV-specific IgG levels are frequently boosted in contrast to that of other herpesviruses indicative of a higher rate of CMV reactivation and antigen-presentation. In contrast to the reactivity of multiple different CLL-rAbs with pUL32, boosts of humoral immunity are triggered apparently by other CMV antigens than pUL32, like glycoprotein B.

show abstract

Kinetics of maternally acquired anti-hepatitis A antibodies: Prediction of waning based on maternal or cord blood antibody levels

Cited by 25 publications

References 45 publications

Time-Series Analysis Comparing the Prevalence of Antibodies against Nine Viral Species Found in Umbilical Cord Blood in Japan

Time-Series Analysis Comparing the Prevalence of Antibodies against Nine Viral Species Found in Umbilical Cord Blood in Japan

Decreasing Risk of Hepatitis A Infection in León, Nicaragua: Evidence from Cross-Sectional and Longitudinal Seroepidemiology Studies

Chronic Lymphocytic Leukemia Patients Have a Preserved Cytomegalovirus-Specific Antibody Response despite Progressive Hypogammaglobulinemia

Contact Info

Product

Resources

About